Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4090-4095

  Wang, Lingzhi ^a   Soon, Gaik Hong ^b   Seng, Kok Yong ^c,e   Li, Jun ^d   Lee, Edmund ^c   Yong, Eu Leong ^d   Goh, Boon Cher ^a   Flexner, Charles ^f   Lee, Lawrence ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e DSO NATIONAL LABORATORIES   (Singapore)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; AGED; CHROMATOGRAPHY, LIQUID; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 80051809442     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00593-11     Document Type: Article

References (22)

1. Arab-Alameddine, M., et al. 2011. Population pharmacokinetics of raltegravir in HIV positive and healthy subjects, oral abstr. O15. Twelfth Int. Workshop Clin. Pharmacol. HIV Ther., Miami, FL, 13 to 15 April 2011.
2. Burger, D M 2010. Raltegravir: A review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin. Drug Metab. Toxicol. 6:1151-1160.
3. Croxtall, J D, K A Lyseng-Williamson, and C M Perry. 2008. Raltegravir. Drugs 68:131-138. (Pubitemid 350275689)
4. Dickinson, L., et al. 2009. An exploratory analysis to determine the feasibility of raltegravir population pharmacokinetics in HIV-infected patients and healthy volunteers, poster P10. Tenth Int. Workshop Clin. Pharmacol. HIV Ther., Amsterdam, The Netherlands, 15 to 17 April 2009.
5. Eron, J E, et al. 2011. QDMRK, a phase III study of the safety & efficacy of once daily (QD) versus twice daily (BID) raltegravir in combination therapy for treatment-naïve HIV-infected patients, abstr. 150LB. Eighteenth Conf. Retroviruses Opportun. Infect., Boston, MA, 27 February to 2 March 2011.
6. Grinsztejn, B., et al. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 369:1261-1269. (Pubitemid 46553846)
7. Hanley, W D, et al. 2008. Effect of atazanavir and ritonavir on raltegravir pharmacokinetics in HIV patients is similar to results obtained in healthy subjects. Clin. Pharmacol. Ther. 83(Suppl. 1):S32.
8. Iwamoto, M., et al. 2008. Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation. J. Clin. Pharmacol. 48:209-214.
9. Iwamoto, M., et al. 2009. Effects of omeprazole on plasma levels of raltegravir. Clin. Infect. Dis. 48:489-492.
10. Kappelhoff, B S, et al. 2005. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin. Pharmacokinet. 44:849-861. (Pubitemid 41126932)
11. Kassahun, K., et al. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35:1657-1663. (Pubitemid 47296061)
12. Lennox, J L, et al. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 374:796-806.
13. Markowitz, M., et al. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515. (Pubitemid 44885615)
14. Merck & Co., Inc. 2007. Isentress (raltegravir) tablets. FDA approved label. Merck & Co., Inc. Whitehouse Station, NJ.
15. Molto, J., et al. 2011. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. Antimicrob. Agents Chemother. 55:72-75.
16. Pommier, Y., A A Johnson, and C. Marchand. 2005. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-248. (Pubitemid 40372557)
17. Simiele, M., et al. 2011. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a Coulter counter to determine intracellular drug concentrations. Antimicrob. Agents Chemother. 55:2976-2978.
18. Steigbigel, R T, et al. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
19. Ter Heine, R., et al. 2010. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pretreated HIV-infected patients. Br. J. Clin. Pharmacol. 69:475-483.
20. Wang, L Z, et al. 2011. Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method. J. Mass Spectrom. 46:202-208.
21. Watson, V., et al. 2011. Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology, poster P01. Twelfth Int. Workshop Clin. Pharmacol. HIV Ther., Miami, FL, 13 to 15 April 2011.
22. Wenning, L A, et al. 2009. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin. Pharmacol. Ther. 85:623-627.